Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose amoxicillin dual therapy versus salvage quadruple therapy for triple-resistant Helicobacter pylori
ChiCTR2100055008Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of amoxicillin, vonoprazan, furazolidone, tetracycline and colloidal bismuth pectin in Helicobacter pylori infection (3 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Helicobacter pylori eradication rate at the end of treatment. Started Jan 2022; status: recruiting.
02
Drugs
amoxicillinvonoprazanfurazolidonetetracyclinecolloidal bismuth pectin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2100055008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100055008.